Given recent evidence demonstrating that PD-L1 inhibition may improve anti-tumor activity in the adjuvant setting, we conducted a single-center phase I/II trial combining chemotherapy and immunotherapy for the neoadjuvant treatment of localized esophageal and GEJ (Siewert I or II) cancer. This evidence concerns the gene CD274 and cancer.